Elevated levels and fragmented nature of cellular fibronectin in the plasma of gastrointestinal and head and neck cancer patients

Clinica Chimica Acta

Volumn 372, Issue 1-2, 2006, Pages 83-93

  Warawdekar, Ujjwala M ^a   Zingde, Surekha M ^a   Iyer, K S N ^b   Jagannath, P ^c   Mehta, Ashok R ^c   Mehta, Narendra G ^a  

^a Research and Education in Cancer   (India)

^b NATIONAL INSTITUTE FOR RESEARCH IN REPRODUCTIVE HEALTH   (India)

^c TATA MEMORIAL HOSPITAL   (India)

Author keywords

Cellular fibronectin; cFN peptides; Invasion; Plasma cFN levels in cancer; Tumor marker

Indexed keywords

CELL PROTEIN; FIBRONECTIN; POLYPEPTIDE; PROTEIN ANTIBODY; PROTEINASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BINDING SITE; BLOOD SAMPLING; CANCER PATIENT; COLON; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GALLBLADDER; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; RNA SPLICING; STATISTICAL SIGNIFICANCE; STOMACH; WESTERN BLOTTING;

AMINO ACID SEQUENCE; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRONECTINS; GASTROINTESTINAL NEOPLASMS; HEAD AND NECK NEOPLASMS; HUMANS; MOLECULAR SEQUENCE DATA;

EID: 33747848399     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2006.03.023     Document Type: Article

References (48)

1. Crawford H.C., and Matrisian L.M. Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invasion Metastasis 14 (1994) 234-245
2. von Bredow D.C., Nagle R.B., Bowden G.T., and Cress A.E. Degradation of fibronectin fibrils by matrilysin and characterization of the degradation products. Exp Cell Res 221 (1995) 83-91
3. Ristelli L.R.J. Analysis of extracellular matrix proteins in biological fluids (1987), Academic Press, New York 391-411 pp.
4. Walker A., and Gallagher J.T. Structural domains of heparan sulphate for specific recognition of the C-terminal heparin-binding domain of human plasma fibronectin (HEPII). Biochem J 317 Pt 3 (1996) 871-877
5. Schwarzbaurer J. The fibronectin gene (1990), Academic Press, San Diego, CA 195-219 pp.
6. Magnuson V.L., Young M., Schattenberg D.G., et al. The alternative splicing of fibronectin pre-mRNA is altered during aging and in response to growth factors. J Biol Chem 266 (1991) 14654-14662
7. Rotundo R.F., Rebres R.A., McKeown-Longo P.J., Blumenstock F.A., and Saba T.M. Circulating cellular fibronectin may be a natural ligand for the hepatic asialoglycoprotein receptor: possible pathway for fibronectin deposition and turnover in the rat liver. Hepatology 28 (1998) 475-485
8. Hershberger R.P., and Culp L.A. Cell-type-specific expression of alternatively spliced human fibronectin IIICS mRNAs. Mol Cell Biol 10 (1990) 662-671
9. Sekiguchi K., and Titani K. Probing molecular polymorphism of fibronectins with antibodies directed to the alternatively spliced peptide segments. Biochemistry 28 (1989) 3293-3298
10. Hocking D.C., Sottile J., and McKeown-Longo P.J. Activation of distinct alpha5beta1-mediated signaling pathways by fibronectin's cell adhesion and matrix assembly domains. J Cell Biol 141 (1998) 241-253
11. Homandberg G.A., Kramer-Bjerke J., Grant D., Christianson G., and Eisenstein R. Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth: structure-function correlations. Biochim Biophys Acta 874 (1986) 61-71
12. Schedin P., Strange R., Mitrenga T., Wolfe P., and Kaeck M. Fibronectin fragments induce MMP activity in mouse mammary epithelial cells: evidence for a role in mammary tissue remodeling. J Cell Sci 113 Pt 5 (2000) 795-806
13. Xie D., and Homandberg G.A. Fibronectin fragments bind to and penetrate cartilage tissue resulting in proteinase expression and cartilage damage. Biochim Biophys Acta 1182 (1993) 189-196
14. Xie D., Hui F., and Homandberg G.A. Fibronectin fragments alter matrix protein synthesis in cartilage tissue cultured in vitro. Arch Biochem Biophys 307 (1993) 110-118
15. Ylatupa S., Haglund C., Mertaniemi P., Vahtera E., and Partanen P. Cellular fibronectin in serum and plasma: a potential new tumour marker?. Br J Cancer 71 (1995) 578-582
16. Castellanos M., Leira R., Serena J., et al. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 35 (2004) 1671-1676
17. Chavarria M.E., Lara-Gonzalez L., Gonzalez-Gleason A., Sojo I., and Reyes A. Maternal plasma cellular fibronectin concentrations in normal and preeclamptic pregnancies: a longitudinal study for early prediction of preeclampsia. Am J Obstet Gynecol 187 (2002) 595-601
18. Choate J.J., and Mosher D.F. Fibronectin concentration in plasma of patients with breast cancer, colon cancer, and acute leukemia. Cancer 51 (1983) 1142-1147
19. Haglund C., Ylatupa S., Mertaniemi P., and Partanen P. Cellular fibronectin concentration in the plasma of patients with malignant and benign diseases: a comparison with CA 19-9 and CEA. Br J Cancer 76 (1997) 777-783
20. Hegele A., Heidenreich A., Kropf J., et al. Plasma levels of cellular fibronectin in patients with localized and metastatic renal cell carcinoma. Tumour Biol 25 (2004) 111-116
21. Hegele A., Heidenreich A., Varga Z., et al. Cellular fibronectin in patients with transitional cell carcinoma of the bladder. Urol Res 30 (2003) 363-366
22. Korner T., Kropf J., Hackler R., Brenzel A., and Gressner A.M. Fibronectin in human bile fluid for diagnosis of malignant biliary diseases. Hepatology 23 (1996) 423-428
23. Peters J.H., Maunder R.J., Woolf A.D., Cochrane C.G., and Ginsberg M.H. Elevated plasma levels of ED1+ ("cellular") fibronectin in patients with vascular injury. J Lab Clin Med 113 (1989) 586-597
24. Probst K., Fijnheer R., Schellekens P., and Rothova A. Intraocular and plasma levels of cellular fibronectin in patients with uveitis and diabetes mellitus. Br J Ophthalmol 88 (2004) 667-672
25. Voskuyl A.E., Emeis J.J., Hazes J.M., van Hogezand R.A., Biemond I., and Breedveld F.C. Levels of circulating cellular fibronectin are increased in patients with rheumatoid vasculitis. Clin Exp Rheumatol 16 (1998) 429-434
26. Hopp T.P., and Woods K.R. Prediction of protein antigenic determinants from amino acid sequences. Proc Natl Acad Sci U S A 78 (1981) 3824-3828
27. Peters J.H., Ginsberg M.H., Bohl B.P., Sklar L.A., and Cochrane C.G. Intravascular release of intact cellular fibronectin during oxidant-induced injury of the in vitro perfused rabbit lung. J Clin Invest 78 (1986) 1596-1603
28. Atherton E., Fox H., Harkiss D., and Sheppard R.C. Application of polyamide resins to polypeptide synthesis: an improved synthesis of beta-endorphin using fluorenylmethoxycarboxyl amino acids. J Chem Soc Chem Commun 13 (1978) 539-540
29. Mayer R.J., and Walker J. Technical supplement, immunochemical methods in cell and molecular biology (1987), Academic Press, San Diego, CA 220-1 pp.
30. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
31. Towbin H., Staehelin T., and Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 76 (1979) 4350-4354
32. Gomez-Lechon M.J., and Castell J.V. Enzyme-linked immunosorbent assay to quantify fibronectin. Anal Biochem 145 (1985) 1-8
33. Armitage P., and Berry G. Statistical methods in epidemiology (1994), Blackwell Scientific Publication 507-34 pp.
34. Okamura Y., Watari M., Jerud E.S., et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 276 (2001) 10229-10233
35. Saad S., Gottlieb D.J., Bradstock K.F., Overall C.M., and Bendall L.J. Cancer cell-associated fibronectin induces release of matrix metalloproteinase-2 from normal fibroblasts. Cancer Res 62 (2002) 283-289
36. Streuli C. Extracellular matrix remodelling and cellular differentiation. Curr Opin Cell Biol 11 (1999) 634-640
37. Garbett E.A., Reed M.W., and Brown N.J. Proteolysis in human breast and colorectal cancer. Br J Cancer 81 (1999) 287-293
38. Ortega N., Behonick D., Stickens D., and Werb Z. How proteases regulate bone morphogenesis. Ann N Y Acad Sci 995 (2003) 109-116
39. Katayama M., Hino F., Kamihagi K., Sekiguchi K., Titani K., and Kato I. Urinary fibronectin fragments (a potential tumor marker) measured by immunoenzymometric assay with domain-specific monoclonal antibodies. Clin Chem 37 (1991) 466-471
40. Cornelius L.A., Nehring L.C., Harding E., et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 161 (1998) 6845-6852
41. O'Reilly M.S., Boehm T., Shing Y., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
42. Ramchandran R., Dhanabal M., Volk R., et al. Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem Biophys Res Commun 255 (1999) 735-739
43. Forsyth C.B., Pulai J., and Loeser R.F. Fibronectin fragments and blocking antibodies to alpha2beta1 and alpha5beta1 integrins stimulate mitogen-activated protein kinase signaling and increase collagenase 3 (matrix metalloproteinase 13) production by human articular chondrocytes. Arthritis Rheum 46 (2002) 2368-2376
44. Lopez-Armada M.J.G.E., Gomez-Guerrero C., and Egido J. The 80 kD fibronectin fragment increases the production of fibronectin and tumour necrosis factor alpha (TNF-a) in cultured mesangial cells. Clin Exp Immunol 107 (1997) 398-403
45. Stanton H., Ung L., and Fosang A.J. The 45 kDa collagen-binding fragment of fibronectin induces matrix metalloproteinase-13 synthesis by chondrocytes and aggrecan degradation by aggrecanases. Biochem J 364 (2002) 181-190
46. Yasuda T., and Poole A.R. A fibronectin fragment induces type II collagen degradation by collagenase through an interleukin-1-mediated pathway. Arthritis Rheum 46 (2002) 138-148
47. Yi M., and Ruoslahti E. A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. Proc Natl Acad Sci U S A 98 (2001) 620-624
48. Judware R., and Culp L.A. Extracellular matrix and matrix receptors: alterations during tumor progression (1997) 660-79 pp.